Display options
Cite
Kurakina АS, Semenova TN, Guzanova EV, et al. Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke. Sovrem Tekhnologii Med. 2021;13(2):68-72doi: 10.17691/stm2021.13.2.08.
Kurakina, �. �. S., Semenova, T. N., Guzanova, E. V., Nesterova, V. N., Schelchkova, N. A., Mukhina, I. V., & Grigoryeva, V. N. (2021). Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke. Sovremennye tekhnologii v meditsine, 13(2), 68-72. https://doi.org/10.17691/stm2021.13.2.08
Kurakina, А S, et al. "Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke." Sovremennye tekhnologii v meditsine vol. 13,2 (2021): 68-72. doi: https://doi.org/10.17691/stm2021.13.2.08
Kurakina АS, Semenova TN, Guzanova EV, Nesterova VN, Schelchkova NA, Mukhina IV, Grigoryeva VN. Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke. Sovrem Tekhnologii Med. 2021;13(2):68-72. doi: 10.17691/stm2021.13.2.08. Epub 2021 Jan 01. PMID: 34513079; PMCID: PMC8353723.
Copy Download .nbib Format: NLM
Share it on

Sovrem Tekhnologii Med. 2021;13(2):68-72. doi: 10.17691/stm2021.13.2.08. Epub 2021 Jan 01.

Prognostic Value of Investigating Neuron-Specific Enolase in Patients with Ischemic Stroke.

Sovremennye tekhnologii v meditsine

А S Kurakina, T N Semenova, E V Guzanova, V N Nesterova, N A Schelchkova, I V Mukhina, V N Grigoryeva

Affiliations

  1. Assistant, Department of Neurology and Medical Genetics, Perm State Medical University named after Academician E.A. Wagner, 26 Petropavlovskaya St., Perm, 614990, Russia.
  2. Assistant, Department of Neurological Diseases, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
  3. Associate Professor, Department of Neurological Diseases, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
  4. Chief of Regional Vascular Center No.23; Head of the Unit for Patients with Acute Disorder of Cerebral Circulation, Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko, 190 Rodionova St., Nizhny Novgorod, 603126, Russia.
  5. Head of the Central Scientific Research Laboratory, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; Associate Professor, Department of Normal Physiology named after N.Y. Belenkov, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
  6. Professor, Director of the Institute of Fundamental Medicine, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia; Head of the Department of Normal Physiology named after N.Y. Belenkov, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.
  7. Professor, Head of the Department of Neurological Diseases, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Square, Nizhny Novgorod, 603005, Russia.

PMID: 34513079 PMCID: PMC8353723 DOI: 10.17691/stm2021.13.2.08

Abstract

MATERIALS AND METHODS: Fifty patients with IS have been examined. On admission to the hospital and at 12-14 days after stroke onset, a clinical and neurological examination have been carried out with the supplementary quantitative assessment of neurological deficit severity according to the National Institutes of Health Stroke Scale (NIHSS), functional outcome according to the Modified Rankin Scale, and Rivermead Mobility Index. Enzyme immunoassay was used to determine NSE concentration in blood plasma in the acute period of the disease.

RESULTS: The NSE level in patients' blood plasma in the first 48 h after stroke onset positively correlates with the ischemic focus volume (r=0.49; p=0.003) and the severity of neurological symptoms (according to NIHSS) (r=0.33; p=0.02). NSE less than 2 ng/ml in the acute disease period is a predictor of good functional outcome 12-14 days after stroke onset (OR=12.4; р=0.006). The NSE level >2.6 ng/ml is associated with a high likelihood of lethal outcome.Neurological deficit below 15 according to NIHSS as well as the NSE level <2 ng/ml in the acute IS period are estimated as prognostic factors of significant recovery of motor function at 2 weeks after disease onset (OR=5.8; р=0.02).

CONCLUSION: Determination of NSE in blood plasma makes it possible to predict functional outcome of the disease development and the recovery of motor function in patients with IS.

Keywords: functional outcome predictors; ischemic stroke; neuron-specific enolase

Conflict of interest statement

Conflict of interest. There are no conflicts of interest related to this study.

References

  1. Stroke. 2016 Jul;47(7):1943-5 - PubMed
  2. Stroke. 1997 Oct;28(10):1956-60 - PubMed
  3. Am J Emerg Med. 2019 Nov;37(11):2051-2054 - PubMed
  4. Clin Chim Acta. 2013 Apr 18;419:136-8 - PubMed
  5. Adv Exp Med Biol. 2015;867:125-43 - PubMed
  6. Clin Chem. 2010 Mar;56(3):451-8 - PubMed
  7. PLoS One. 2014 Sep 04;9(9):e106680 - PubMed
  8. Crit Care. 2016 Sep 08;20:285 - PubMed
  9. Arch Neurol. 2003 Jan;60(1):37-41 - PubMed
  10. Cerebrovasc Dis. 2012;33(1):47-54 - PubMed
  11. Clin Neurol Neurosurg. 2006 Sep;108(6):558-63 - PubMed
  12. Clin Biochem. 2012 Nov;45(16-17):1302-7 - PubMed
  13. Disabil Rehabil. 2001 Oct 15;23(15):670-6 - PubMed
  14. Ann Indian Acad Neurol. 2013 Oct;16(4):504-8 - PubMed

Publication Types